Hospital

Amesh Adalja, MD, FIDSA, FACP, FACEP, said that the efficacy of COVID-19 booster vaccines against variants of concern is still relatively unknown, although administering the third shots does increase antibodies as expected.

Non-alcoholic steatohepatitis is the most severe form of non-alcoholic fatty liver disease.

Atrial fibrillation, bleeding, infection, and other adverse events may occur with this therapy.

This has caused an ongoing problem with mistrust in many vaccines and medications, since there is still uncertainty surrounding how they affect other races and ethnicities.

Specific infection-fighting cells of the immune system found to be downregulated, offering a potential clue to the cause of prolonged COVID-19 illness in children.

The FDA has granted orphan drug designation to CFT7455 for the treatment of multiple myeloma, according to a press release from manufacturer C4 Therapeutics.

The designation highlights the need for new treatment options for patients with platinum-resistant ovarian cancer and the significant treatment potential of IN10018, according to a press release from InxMed, the manufacturer of the novel drug.

An announcement from CDC officials recommending COVID-19 boosters for all adults could come as soon as this week, although doses would only be widely administered once the FDA formally approved the vaccines.

Ridinilazole is not currently approved for use by any regulatory authority.

The approval marks the first HIF-2α inhibitor therapy approved in the United States for some types of Von Hippel-Lindau disease-associated tumors.

Approval sought for oportuzumab monatox-qqrs (Vicinium) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), which was previously granted priority review by the FDA.

The pandemic taught the pharmacy to provide a deeper level of personalized care and communication than in the past.

Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the FDA’s new guidance Project Optimus, which addresses issues relating to dose optimization in clinical trials assessing oncology drugs.

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) was approved in July in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma following their first or subsequent relapse.

New treatments show promise for patients with KRAS G12C–mutated disease.

The FDA recently authorized COVID-19 vaccine booster shots for immunocompromised individuals, who comprise about 3% of the US population.

Analyzing how off-target antibodies may be undermining HIV vaccine prototypes allows for design improvements.

The FDA approved pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced RCC.

Patients with microsatellite stable (MSS) colorectal cancer, which represents 95% of all metastatic colorectal cancer cases, are more responsive to checkpoint blockade immunotherapy if the patient’s tumors have not spread to the liver.

The investigators found that antibodies generated by a single dose of the Pfizer-BioNTech vaccine was less effective at neutralizing variants of concern, but the second dose dramatically increased responses to virus variants.

The FDA is expected to recommend that individuals with compromised immune systems receive a booster shot of either the Pfizer or Moderna COVID-19 vaccine.

The CDC now recommends COVID-19 vaccination for all individuals 12 years and older in the United States, including those who are pregnant or breastfeeding.

If approved, pembrolizumab would be the first adjuvant immunotherapy option for this patient population with renal cell carcinoma.

The safety of atezolizumab in the Impower010 trial was consistent with its known safety profile and no new safety signals were identified.

Among those who had hypertension, diabetes, and/or obesity as well as COVID-19, the risk rose to 160%.

The requirement to promote a healthy, productive, and safe work environment is borne by all, not just those with a managerial title.

Current guideline recommendations include various combinations of targeted therapy with immunotherapy.

Study suggests that immediate onset mRNA vaccine reactions may not be caused by classic allergy, or IgE-mediated hypersensitivity.